Which is better, ENOV or HALO?

On the Buffett-Fit framework, Halozyme Therapeutics, Inc. (HALO) currently grades higher than ENOV — 69/100 (B grade) vs 18/100 (F). That said, "better" depends on which framework you trust — ENOV wins on none; HALO wins on Warren Buffett, Benjamin Graham, Philip Fisher, Peter Lynch, Joel Greenblatt, Charlie Munger, and Terry Smith. The full pillar breakdown is on this page.

Should I buy ENOV or HALO?

This page is an educational comparison, not investment advice. Both ENOV and HALO are graded against the same Buffett 5-pillar framework (moat, earnings durability, management quality, financial health, valuation) plus six other documented investor frameworks. Read the side-by-side breakdown to see which one matches the criteria you care about most — and always do your own research before making any investment decision.

Is ENOV better than HALO for value investing?

On the Buffett-style value-investing framework, HALO currently grades higher — 69/100 vs 18/100, a 51-point gap. The gap is driven by which pillars each stock passes; the table on this page shows moat, durability, management, financial health, and valuation side-by-side.

What's the difference between ENOV and HALO on Warren Buffett's framework?

Both stocks are evaluated on the same five pillars: economic moat (durable competitive advantage), earnings durability (consistent profitability), management quality (capital allocation), financial health (conservative balance sheet), and valuation (margin of safety). ENOV currently scores 18/100 (F grade); HALO scores 69/100 (B grade). The "Where each wins" section on this page breaks down which pillar each stock dominates.

Which has the stronger moat, ENOV or HALO?

Moat strength is one of the five pillars in the Buffett-Fit score on this page. ENOV and HALO are each scored on ROIC sustainability, gross-margin durability, and qualitative signals like brand strength, switching costs, network effects, and regulatory barriers. The pillar breakdown on this page shows the moat sub-score side-by-side so you can see which one has the more durable competitive advantage.

Which is more undervalued, ENOV or HALO?

Valuation is one of the five Buffett-Fit pillars on this page. Both stocks are scored on owner-earnings yield, price-to-intrinsic-value vs the underlying compounding rate, and the margin of safety relative to a conservative DCF. The valuation sub-score in the table below tells you which one currently trades at a more attractive price relative to its underlying business quality.

Are ENOV and HALO both Healthcare stocks?

Yes — both Enovis Corporation (ENOV) and Halozyme Therapeutics, Inc. (HALO) operate in the Healthcare sector. That makes this a direct sector-peer comparison, which is the apples-to-apples way to use the Buffett-Fit framework: the score weighs each stock against its sector's specific quality and valuation benchmarks (sector-relative bonus), so the cross-stock comparison isn't distorted by inter-sector base-rate differences.

Is this ENOV vs HALO comparison investment advice?

No. This page is an educational pattern-match against documented public frameworks (Buffett, Graham, Fisher, Lynch, Greenblatt, Munger, Smith), not personalised investment advice. The scores reflect how closely each stock matches each framework's documented criteria — they are not buy/hold/sell recommendations. Always do your own research and consult a licensed financial adviser for personalised advice.

Stock comparison

Enovis

Halozyme Therapeutics

Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.

ENOV

Enovis

Market cap

$1.4B

Sector

Healthcare

HALO

Halozyme Therapeutics

Market cap

$8.41B

Sector

Healthcare

Overall winner

Halozyme Therapeutics HALO

Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.

Fit scores by strategy

Strategy	ENOV	HALO	Winner
Warren Buffett	18F	69B	HALO
Benjamin Graham	18F	73B	HALO
Philip Fisher	27F	55C	HALO
Peter Lynch	30F	43D	HALO
Joel Greenblatt	0F	30F	HALO
Charlie Munger	24F	70B	HALO
Terry Smith	20F	74B	HALO

Side-by-side metrics

Metric	ENOV	HALO
Market cap	$1.4B	$8.41B
P/E (TTM)	-	24.0x
EV/EBIT	-	10.2x
ROIC (TTM)	1.87%	23.65%
Gross margin	56.81%	81.24%
Net margin	-49.91%	23.13%
Revenue CAGR 5y	12.05%	33.23%
EPS CAGR 5y	-	-1.98%
Debt / Equity	1.0x	1.0x
Dividend yield	0.0%	0.0%

Where each one wins

The metrics with the biggest gap between the two - sorted so the most decisive edges read first.

ENOV leads on

EV/EBIT-vs 10.2x+107%
P/E (TTM)-vs 24.0x+105%

HALO leads on

Net margin23.13%vs -49.91%+146%
ROIC (TTM)23.65%vs 1.87%+92%
Market cap$8.41Bvs $1.4B+83%
Revenue CAGR 5y33.23%vs 12.05%+64%

More like ENOV

ENOV vs IDXX ENOV vs 7741.T ENOV vs GMAB ENOV vs LMAT ENOV vs SUNPHARMA.NS ENOV vs MTD

More like HALO

HALO vs IDXX HALO vs 7741.T HALO vs GMAB HALO vs LMAT HALO vs SUNPHARMA.NS HALO vs MTD

Read the full Buffett-Brain analysis for ENOV Read the full Buffett-Brain analysis for HALO

Related on invest-like

Strongest Moat Highest ROIC Warren Buffett strategy Economic Moat

Key terms in this analysis

ROIC Free Cash Flow (FCF)Economic Moat P/E Ratio Margin of Safety Quality Score

Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.

Stock comparison

Enovis

Halozyme Therapeutics

Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.

ENOV

Enovis

Market cap

$1.4B

Sector

Healthcare

HALO

Halozyme Therapeutics

Market cap

$8.41B

Sector

Healthcare

Overall winner

Halozyme Therapeutics HALO

Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.

Fit scores by strategy

Strategy	ENOV	HALO	Winner
Warren Buffett	18F	69B	HALO
Benjamin Graham	18F	73B	HALO
Philip Fisher	27F	55C	HALO
Peter Lynch	30F	43D	HALO
Joel Greenblatt	0F	30F	HALO
Charlie Munger	24F	70B	HALO
Terry Smith	20F	74B	HALO

Side-by-side metrics

Metric	ENOV	HALO
Market cap	$1.4B	$8.41B
P/E (TTM)	-	24.0x
EV/EBIT	-	10.2x
ROIC (TTM)	1.87%	23.65%
Gross margin	56.81%	81.24%
Net margin	-49.91%	23.13%
Revenue CAGR 5y	12.05%	33.23%
EPS CAGR 5y	-	-1.98%
Debt / Equity	1.0x	1.0x
Dividend yield	0.0%	0.0%

Where each one wins

The metrics with the biggest gap between the two - sorted so the most decisive edges read first.

ENOV leads on

EV/EBIT-vs 10.2x+107%
P/E (TTM)-vs 24.0x+105%

HALO leads on

Net margin23.13%vs -49.91%+146%
ROIC (TTM)23.65%vs 1.87%+92%
Market cap$8.41Bvs $1.4B+83%
Revenue CAGR 5y33.23%vs 12.05%+64%

More like ENOV

ENOV vs IDXX ENOV vs 7741.T ENOV vs GMAB ENOV vs LMAT ENOV vs SUNPHARMA.NS ENOV vs MTD

More like HALO

HALO vs IDXX HALO vs 7741.T HALO vs GMAB HALO vs LMAT HALO vs SUNPHARMA.NS HALO vs MTD

Read the full Buffett-Brain analysis for ENOV Read the full Buffett-Brain analysis for HALO

Related on invest-like

Strongest Moat Highest ROIC Warren Buffett strategy Economic Moat

Key terms in this analysis

ROIC Free Cash Flow (FCF)Economic Moat P/E Ratio Margin of Safety Quality Score

Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.